References
- Ralph SJ, Weissenberger A, Bonev V, et al. Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation. Expert Opin Investig Drugs. 2020;1–16. DOI: 10.1080/13543784.2020.1709822
- Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother. 2010;10(6):985–1002.
- Tobinick EL. Perispinal Delivery of CNS Drugs. CNS Drugs. 2016;30:469–480.
- Smythe H. Therapy of the spondyloarthropathies. Clin Orthop Relat Res. 1979;143:84–89.
- Clark IA. How TNF was recognized to be a key mechanism of disease. Cytokine Growth Factor Rev. 2007;18:335–343.
- Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010;128:519–548.
- Clark IA, Vissel B. Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective - a Commentary. Expert Rev Neurother. 2019;19(6):535–543.
- Tobinick E, Vega CP. The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed. 2006;8(1):53.
- Tobinick EL, Gross H, Weinberger A, et al. TNF-alpha modulation for treatment of Alzheimer’s disease: A 6- month pilot study. Medscape Gen Med Neurol Neurosurg. 2006;8(2):25.
- Wen TS, Randall DC, Zolman JF. Protein accumulation in cerebrospinal fluid during −90 degrees head-down tilt in rabbit. J Appl Physiol. 1994;77(3):1081–1086.
- Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes. 2009;2:28.
- LaMacchia ZM, Spengler RN, Jaffari M, et al. Perispinal injection of a TNF blocker directed to the brain of rats alleviates the sensory and affective components of chronic constriction injury-induced neuropathic pain. Brain Behav Immun. 2019;82:93–105.
- Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011;25(2):145–155.
- Tobinick E, Kim NM, Reyzin G, et al. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26(12):1051–1070.
- Ignatowski TA, Spengler RN, Dhandapani KM, et al. Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs. 2014;28:679–697.
- Ignatowski TA, Spengler RN, Tobinick E. Authors’ reply to Whitlock: perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs. 2014;28(12):1207–1213.
- Tobinick E. Perispinal etanercept advances as a neurotherapeutic. Expert Rev Neurother. 2018;18(6):453–455.
- Clark IA. Editorial: an unsound AAN practice advisory on poststroke etanercept. Expert Rev Neurother. 2017;17(3):215–217.
- Tobinick E. Immediate resolution of hemispatial neglect and central post-stroke pain after perispinal etanercept: case report. Clin Drug Investig. 2020;40(1):93–97.
- Clark IA, Vissel B. A neurologist’s guide to TNF biology and to the principles behind the therapeutic removal of excess TNF in disease. Neural Plast. 2015;358263.
- Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science. 2003;301(5641):1895–1898.
- Barnum CJ, Chen X, Chung J, et al. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro(R)1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. J Parkinsons Dis. 2014;4(3):349–360.
- Olleros ML, Vesin D, Lambou AF, et al. Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guerin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Infect Dis. 2009;199(7):1053–1063.